论文部分内容阅读
CYP3A4基因是调控抗血小板聚集药物氯吡格雷代谢的重要因素之一，以往的研究发现个体间存在CYP3A4基因多态性现象，且不同的突变位点导致临床上患者对氯吡格雷的效价差异。其中氯吡格雷抵抗现象会明显增加患者再发次级心血管事件的概率，但最近的国内外试验发现氯吡格雷抵抗与CYP3A4基因多态性的相关性及其指导患者抗血小板药物的个体化治疗作用并不十分明确。为此，现对其新近的研究成果做一概述。“,”CYP3A4 gene is one of the important factor in regulating the metabolism of antiplatelet aggregation drug clopidogrel.The previous studies have found that CYP3A4 gene polymorphism exists among individuals,and different mutations cause patients to clopidogrel potency differences.Clopidogrel resistance is a significant increase in the risk of recurrence of secondary cardiovascular events.However,re-cent domestic and foreign trials have found that the association between clopidogrel resistance and CYP3A4 gene polymorphisms and the indi-vidual therapy of antiplatelet drugs in patients with their guidance is not very clear.To this end,it is a summary of the recent research results.